



Restoring fertility

April 2026

Contact: Florent Ferré, CEO
florent.ferre@igyxos.com



Igyxos overview

Founded in **2017**,
based in **France**





La science pour la santé
From science to health

- Headquarters in Nouzilly, Tours (France)
- IGX12 Lead program targeting Phase 2 start in 2026
- Strong IP portfolio
- >€25m secured since inception
- Serie A round ongoing

Humanity is facing a major global **fertility crisis**


- **1 in 6 couples globally¹** have infertility issues
- In developed countries, fertility rates, **below** population replacement rate, are a major **economic threat**
- The prevalence of infertility is **sharply increasing** driven by



There is a high **unmet need** around infertility



Men are the cause of nearly **50%** of infertility but there is **no** approved therapy



Women bear all the burden of infertility, despite **low** success rate of In Vitro Fertilization (IVF) ¹
(25% after 1 cycle)

The global fertility market was valued at **\$35bn²** in 2023 (out of which Gonadotropin rep. **10%**) and is projected to grow to **\$63bn** in the next **10 years**

At the forefront of reproductive medicine, Igyxos Biotherapeutics is revolutionizing infertility treatment with a novel, game-changing approach.

- **First-in-class lead asset (IGX12)** with a **differentiated mechanism of action** that enhances gametogenesis and addresses the underlying biology of infertility in both men and women
- **Bold ambition to deliver significant commercial opportunity** driven by:
 - The **first-ever approved therapy for male infertility**, and
 - **Superior outcome in women** compared to current standard-of-care options
- **Robust foundation of pre-clinical and Phase I data** supports IGX12's differentiated profile, with **Phases II trials planned to initiate in 2026** for both male and female indications
- **€30m+ Serie A round targeted for Q1 2026**, aimed at funding Phase II clinical development and unlocking IGX12's full therapeutic and commercial potential